drugset / Trial / NCT06587217

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm

NCT06587217

NaSingle-groupOpen-labelBasic science

Summary

Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that \~20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this open-label study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.

Timeline

Start
2024-10-29
Primary completion
2025-04-03
Completion
2025-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 25 mg Oral
Subject Levodopa Small molecule 37.5 mg Oral
Subject Levodopa Small molecule 150 mg Oral

Indications